Syndesi Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Syndesi Therapeutics's estimated annual revenue is currently $3.1M per year.
- Syndesi Therapeutics's estimated revenue per employee is $155,000
Employee Data
- Syndesi Therapeutics has 20 Employees.
- Syndesi Therapeutics grew their employee count by 11% last year.
Syndesi Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Head Programs and Clinical Operations | Reveal Email/Phone |
2 | Medical Director | Reveal Email/Phone |
Syndesi Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $81.4M | 375 | 40% | N/A | N/A |
#2 | $16.9M | 109 | 22% | N/A | N/A |
#3 | $156.1M | 120 | -70% | $145M | N/A |
#4 | $2.9M | 37 | -24% | $150M | N/A |
#5 | $1.3M | 17 | 0% | $459.5M | N/A |
#6 | $49.2M | 254 | 15% | $180.7M | N/A |
#7 | $7M | 45 | -2% | N/A | N/A |
#8 | $256.3M | 840 | 9% | $168.5M | N/A |
#9 | $4.2M | 27 | -7% | N/A | N/A |
#10 | $10.1M | 65 | 5% | N/A | N/A |
What Is Syndesi Therapeutics?
Syndesi Therapeutics is developing molecules that uniquely modulate the synaptic vesicle protein SV2A, which plays a central role in synaptic transmission (the communication between neurons in the brain). Regulating synaptic transmission represents a promising approach to treating Alzheimer's Disease and other disorders with cognitive impairment. Syndesi has an exclusive license to its platform technology from UCB, the leading company in SV2A research.
keywords:N/A
N/A
Total Funding
20
Number of Employees
$3.1M
Revenue (est)
11%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Syndesi Therapeutics News
AbbVie has bolstered its neuropsychiatric and neurodegenerative portfolio with the acquisition of Belgium-based Syndesi Therapeutics in a...
Founded in December 2017 and based in Belgium, Syndesi is a clinical stage biotechnology company pioneering the development of novel...
Syndesi Therapeutics is one of several Novo Seeds portfolio companies focused on developing better treatments for CNS disorders, an area of...
Other Companies in Louvain-la-Neuve
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $2M | 20 | -44% | N/A |
#2 | $2.4M | 24 | N/A | N/A |
#3 | N/A | 48 | 45% | N/A |
#4 | $7.5M | 67 | 2% | N/A |
#5 | $13.8M | 73 | 26% | N/A |